"You have a medication that looks to be just as good as Paxlovid, but less cumbersome," said Dr. Panagis Galiatsatos, an assistant professor of medicine at Johns Hopkins Medicine in Baltimore.
Bimodal olfactory training with visual cues and the use of patient-preferred scents did not produce a clinically meaningful improvement in sense of smell among individuals with COVID-19–related olfactory loss, a 275-patient randomized trial showed.
In this video, MedPage Today editor-in-chief Jeremy Faust, MD, sits down with allergist and immunologist Zachary Rubin, MD, of Oak Brook Allergists in Illinois, to discuss the lasting effects of COVID-19 on pediatric health.
/cloudfront-us-east-2.images.arcpublishing.com/reuters/OKOTQVLKDVNWZAELOIOUZQRVZI.jpg)
